| AS/AQ Project Partners |
| |
The success of the AS/AQ project fulfils DNDi's goal to bring together the skills and know-how of various scientific, university, public and private partners in developing and developed countries. This success was made possible by the participation of the WHO/TDR programme, TropiVal, Université de Bordeaux 2, Universiti Sains Malaysia, the University of Oxford, and Burkina Faso's National Malaria Research and Training Centre.
TropiVal of the University Victor Segalen of Bordeaux 2 (France), a centre for pharmaceutical projects focused on developing drugs for tropical and neglected diseases, and one of the principal FACT contractors. TropiVal helped identify several public institutions and private companies and contributed to the coordination of their work to insure completion of the various pharmaceutical steps of the project. It contributed to coordinate the pharmaceutical development of fixed-dose combinations of artesunate and amodiaquine
Universiti Sains Malaysia (Centre for Drug Research, CDR): The Centre for Drug Research, Universiti Sains Malaysia, established in 1980 by the Government of Malaysia is an independent research and training centre within the administrative governance of USM. The CDR developed analytical methods which were the base of the quality control of the finished products. It also developed the bioanalytical methods for the project to carry out all the trials of biological samples from animal studies as well as the bio-availability and various clinical studies. It is also responsible for the phase 1 pharmacokinetic study of the new FDC and the bioanalytical and pharmacokinetic analysis.
The Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Ougadougou, Burkina Faso : The "Centre National de Recherche et de Formation sur le Paludisme (CNRFP) is part of the Burkina Faso Ministry of Health. The CNRFP participates in the formulation, implementation, supervision and evaluation of the national programme for malaria control. This includes carrying out operational and basic research projects to identify new malaria control tools and to adapt existing ones to local conditions and ensuring training on malaria for local health staff and scientists from Burkina Faso and other African countries. CNRFP is working on Phase III clinical trials and pharmacokinetics in patients. It contributes to the organization and the performance of the field study in patients comparing the safety/efficacy of the new FDC with the free combination. CNRFP is also responsible for the clinical part of the Population pharmacokinetic study.
Tropical Disease Research-WHO (TDR) shared its extensive experience by:
- Using a large data-base to determine the best fixed-ratio composition of both components in the combination and design optimal weight/age adapting dosing schedule
- Using its capacity building programs and networks to identify possible individual partners and activities to participate in the project. Contributing to the scientific plan and management of the program and particularly to the clinical components of the FACT project.
University of Oxford, Centre for Tropical Medicine: Experts from Oxford have been heavily involved in research on Artemisinin combinations in South East Asia, the starting point of the FACT project. Professor N.White is also the Chairman of the annual FACT team meetings. Oxford will continue to be involved in the AS-AQ fixed dose combination project through the analysis of the population PK data and possible pharmacokinetic-pharmacodynamic relationships.
|
| |
| << previous |
next >> |